GHRP-2 and Retatrutide Interaction: Monitor | Peptide Database

Join others researching Finasteride — share findings, ask questions, and learn from real experiences Finasteride is an FDA-approved 5-alpha reductase inhibitor that blocks the conversion of testosterone to dihydrotestosterone (DHT), the primary androgen responsible for androgenetic alopecia (male pattern hair loss) and benign prostatic hyperplasia (BPH). At 1mg daily, it reduces scalp DHT levels by approximately 66%, slowing or halting hair loss in roughly 90% of men and producing visible regrowth in about 48% over one to two years. Originally developed for prostate enlargement at 5mg (Proscar), the lower 1mg dose (Propecia) was approved specifically for hair loss in 1997. It remains one of only two FDA-approved oral treatments for androgenetic alopecia and has decades of long-term safety data. Finasteride competitively and selectively inhibits the Type II isoform of the enzyme 5-alpha reductase, which is predominantly found in hair follicles, the prostate, and the liver. This enzyme converts testosterone into dihydrotestosterone (DHT). By blocking this conversion, finasteride reduces serum DHT levels by approximately 70% and scalp DHT by roughly 66% at the 1mg dose. Since DHT is the primary androgen driving miniaturization of hair follicles in genetically susceptible individuals, lowering DHT levels allows affected follicles to recover, extend the anagen (growth) phase, and produce thicker terminal hairs. Notably, finasteride does not block androgen receptors and has minimal effect on testosterone levels, which may increase slightly (by about 10-15%) as a compensatory response to reduced DHT.

Winlevi (clascoterone cream 1%) is FDA-approved for the topical treatment of acne vulgaris in patients 12 years and older. Phase 3 trials demonstrated statistically significant reductions in inflammatory and non-inflammatory lesion counts compared to vehicle, with an Investigator Global Assessment success rate significantly higher than placebo. Particularly relevant for women with androgen-driven acne who cannot tolerate or prefer to avoid systemic anti-androgens like spironolactone. Provides targeted anti-androgen activity at the sebaceous gland without the systemic effects, menstrual irregularities, or contraindication in pregnancy associated with oral anti-androgens. Breezula (clascoterone solution 7.5%) has completed Phase 3 clinical trials for androgenetic alopecia in men. Trial results showed improvements in target area hair count compared to vehicle. Regulatory submission is pending. The topical anti-androgen approach offers a potential alternative to systemic 5-alpha reductase inhibitors for men concerned about systemic side effects. The favorable safety profile and lack of systemic anti-androgenic effects make clascoterone a candidate for female androgenetic alopecia, where systemic anti-androgens carry teratogenic risks. Clinical data in women for this indication is still being developed.